# Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

Study · id `cardio:ct-nct06767345` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06767345](<https://clinicaltrials.gov/study/NCT06767345>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06767345

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 410 participants.

## Technical summary

Registry record NCT06767345. Randomized; no masking; primary purpose treatment. Start 2025-05-12 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 410 participants (enrolled count; ClinicalTrials.gov record NCT06767345, source copy `cardio:ctgov-nct06767345-2026-10-26`, retrieved 2026-10-31)
- Started: 2025-05-12 (actual) (ClinicalTrials.gov record NCT06767345, source copy `cardio:ctgov-nct06767345-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT06767345, source copy `cardio:ctgov-nct06767345-2026-10-26`, retrieved 2026-10-31)
- Completion: 2028-06-25 (anticipated) (ClinicalTrials.gov record NCT06767345, source copy `cardio:ctgov-nct06767345-2026-10-26`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06767345, source copy `cardio:ctgov-nct06767345-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06767345-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
- Condition: Coronary Artery Disease
- Condition: Atherosclerosis of Coronary Artery
- Condition: Plaque, Atherosclerotic
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Rosuvastatin/ezetimibe
- Lead sponsor: Korea University Anam Hospital
- Lead sponsor class: OTHER
- Collaborator: Yuhan Corporation
- Collaborator class: INDUSTRY
- Collaborator: Hanmi Pharmaceutical co., ltd.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Korea University Anam Hospital (`cardio:org-korea-university-anam-hospital`)
- Registry lists this organization as a collaborator: Yuhan Corporation (`cardio:org-yuhan-corporation`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical co., ltd. (`cardio:org-hanmi-pharmaceutical-co-ltd`)

## Provenance

Content hash: c7446cbacd02401d797a6ac95758fd26c093a7f908d22da638f0707ffd5d56e7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
